Unibest
← Back to patent-cliff list

Cofrogliptin

Tier C — Watch / trade

Cofrogliptin

-
Originator
2024
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:DPP4

Indications (approved):Type 2 diabetes

Regional status

US
-
EU
-
China
Approved
2024-06-18
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Cofrogliptin?

Approved indications include: Type 2 diabetes.

When does the Cofrogliptin patent expire?

No public expiry year is available for Cofrogliptin yet; this page updates once verified.

How do I get a quote for Cofrogliptin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27